SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN)
AVAN 10.040.0%Jun 12 9:41 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: invbiotech11/17/2006 2:41:22 PM
   of 513
 
Rotavirus infection (among others) as a potential trigger of type 1 diabetes in genertically susceptible patients. AVAN's Rotarix vaccine against rotavirus is one of 2 globally marketed rota vaccines (Glaxo is the partner).

Diabetes Metab Res Rev. 2006 Nov 14; [Epub ahead of print] Links
Viral infections as potential triggers of type 1 diabetes.van der Werf N, Kroese FG, Rozing J, Hillebrands JL.
Department of Cell Biology, Immunology Section, University Medical Center Groningen, University of Groningen, The Netherlands.

During the last decades, the incidence of type 1 diabetes (T1D) has increased significantly, reaching percentages of 3% annually worldwide. This increase suggests that besides genetical factors environmental perturbations (including viral infections) are also involved in the pathogenesis of T1D. T1D has been associated with viral infections including enteroviruses, rubella, mumps, rotavirus, parvovirus and cytomegalovirus (CMV). Although correlations between clinical presentation with T1D and the occurrence of a viral infection that precedes the development of overt disease have been recognized, causalities between viruses and the diabetogenic process are still elusive and difficult to prove in humans. The use of experimental animal models is therefore indispensable, and indeed more insight in the mechanism by which viruses can modulate diabetogenesis has been provided by studies in rodent models for T1D such as the biobreeding (BB) rat, nonobese diabetic (NOD) mouse or specific transgenic mouse strains. Data from experimental animals as well as in vitro studies indicate that various viruses are clearly able to modulate the development of T1D via different mechanisms, including direct beta-cell lysis, bystander activation of autoreactive T cells, loss of regulatory T cells and molecular mimicry. Data obtained in rodents and in vitro systems have improved our insight in the possible role of viral infections in the pathogenesis of human T1D. Future studies will hopefully reveal which human viruses are causally involved in the induction of T1D and this knowledge may provide directions on how to deal with viral infections in diabetes-susceptible individuals in order to delay or even prevent the diabetogenic process. Copyright (c) 2007 John Wiley & Sons, Ltd.

PMID: 17103489 [PubMed - as supplied by publisher]
Related LinksControl of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice. [Ann N Y Acad Sci. 2005] PMID: 16126946 A new look at viruses in type 1 diabetes. [Diabetes Metab Res Rev. 2003] PMID: 12592641 Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. [J Virol. 2002] PMID: 12414951 Viruses and diabetes. [Ann N Y Acad Sci. 2002] PMID: 12021080 Diabetes resistance/susceptibility in T cells of nonobese diabetic mice conferred by MHC and MHC-linked genes. [J Immunol. 2005] PMID: 16210629 See all Related Articles...

ncbi.nlm.nih.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext